HAMRI CO., LTD．

HAMRI is a GLP contract research organization (CRO) offering non-clinical study for pharmaceutical and regenerative medicine, fully AAALAC-accredited facilities.

The company has extensive expertise in various disease models and strong capabilities in providing support from the study design stage.

Features of HAMRI’s Non-Clinical Study Services

Comprehensive coverage of pharmacodynamics, safety, and pharmacokinetics

HAMRI undertakes all three core areas of non-clinical testing—pharmacodynamic studies, safety studies, and pharmacokinetic studies—in-house.
The company conducts efficacy evaluations in various animal models in diabetes, autoimmune diseases, and Parkinson’s disease.

Under GLP compliance, HAMRI also performs safety evaluations including toxicity and genotoxicity studies, as well as pharmacokinetic analyses of absorption, distribution, metabolism, and excretion (ADME).
With an integrated system that covers study design, data analysis, and report preparation, they offer flexible and tailored design for clients’ needs.

GLP-compliant facilities and full AAALAC accreditation

In addition to being fully GLP compliant, they are also fully accredited by AAALAC International, a global organization that evaluates and certifies laboratory animal care.
By combining scientific reliability with animal welfare, HAMRI has earned the trust of regulatory authorities and pharmaceutical companies both in Japan and globally.

They continue to implement various protocols to ensure high-quality and safe testing environment.

A wide range of disease models, including STZ-induced Type I diabetes

HAMRI provides a broad selection of animal models for various diseases, including STZ (streptozotocin)-induced Type I diabetes models.
They deliver highly accurate efficacy evaluations for specific disease targets.

In the diabetes model, they offer multifaceted evaluation parameters— change in blood glucose levels, insulin secretion level—which allow detailed verification of the efficacy and mechanism of action of candidate compounds.

Disease Model available at HAMRI

STZ-induced Type I diabetes mellitus in a crab-eating monkey model

HAMRI has Type I diabetes mellitus model in crab-eating monkeys.
This model is induced by streptozotocin (STZ), which is used for pharmacological efficacy studies.
As a diabetes model, detailed efficacy evaluations can be conducted based on multiple indications, changes in blood glucose and insulin secretion level.

They can also co-develop a long-term exploratory study with the same animal for prolonged period of time.

You can expect gaining valuable data for drug discovery or investigating disease mechanism of action. Standard analysis includes sample analyses using ELISA, real-time PCR, and FACS.

Reference:
https://www.hamri.co.jp/medicinal-effect

HAMRI’s Non-Clinical Study Case Example

STZ-induced Type I diabetes model in micromini pigs

HAMRI have developed STZ-induced Type I diabetes model in micromini pigs. They measure blood glucose levels over time.
In this study, a continuous glucose sensor was implanted subcutaneously to track the progression of diabetes in real time, demonstrating an innovative evaluation approach for new diabetes models that contributes to drug discovery research.

This is a valuable case study from HAMRI’s. It was recorded through an external presentation.

Reference:
https://www.hamri.co.jp/seminar02

Company Information